ADLS: CEO Discusses Positive QT Study and Development of Cethromycin
[?]
Submitted By Knobias ClipReport
Advanced Life Sciences Holdings, Inc. (ADLS) was higher on Tuesday after the Company announced positive results from Trial CL07-001, a thorough QT study of the Company’s novel once-a-day oral antibiotic, cethromycin. This study was conducted to evaluate the cardiac safety of cethromycin and to enhance the safety database for the Company’s upcoming New Drug Application (NDA) submission for cethromycin to treat community acquired pneumonia (CAP). The FDA requires thorough QT studies for all new chemical entities because prolongation in QT interval (corrected for changes in heart rate, or QTc, may signify an increased risk of developing cardiac arrhythmias.
